Bingjuan Li

Dr. Bingjuan Li

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2022 in Food Science & Nutrition
Verified
Journal Article
Open access
BLBingjuan Li
Bingjuan Li
MXMeng‐Ying Xiao
Meng‐Ying Xiao
XDXin‐Yu Dong
Xin‐Yu Dong
ZHZhao‐Xiang Huang
Zhao‐Xiang Huang
(S)-equol, the most active metabolite of the soybean isoflavones in vivo, has exhibited various biological activities and clinical benefits. Existing studies on the heterologous biosynthesis of (S)-equol via the engineered E. coli constructed have been significantly progressed. In the present study, the engineered E. coli was further improved to be more suitable for (S)-equol production. The four enzymes involved in the biosynthesis of (S)-equol and another GDH for NADPH regeneration were combined to construct the recombinant E. coli BL21(DE3). The optimal conditions for (S)-equol production were explored, respectively. The yield of equol reached 98.05% with 1 mM substrate daidzein and 4% (wt/vol) glucose. Even when the substrate concentration increased to 1.5 mM, (S)-equol could maintain a high yield of 90.25%. Based on the 100 ml one-pot reaction system, (S)-equol was produced with 223.6 mg/L in 1.5 h. The study presented a more suitable engineered E. coli for the production of (S)-equol.

10 October 2019 in Journal of Food Processing and Preservation
Verified
Journal Article
Closed access
PDF file
BLBingjuan Li
Bingjuan Li

9 January 2026 in Food Science & Nutrition
Verified
Journal Article
Open access
JZJiao‐Jiao Zhuo
Jiao‐Jiao Zhuo
BLBingjuan Li
Bingjuan Li
MTMeng‐Ran Tian
Meng‐Ran Tian
Equol is a metabolite transformed from daidzein by intestinal microorganisms and has received extensive attention due to its various pharmacological activities and therapeutic potential. In recent years, with the in‐depth study of the biological activity of equol, the development of its derivatives has gradually become a research hotspot. These derivatives may exhibit stronger biological activities or more extensive pharmacological effects through structural modification or functional optimization. This review describes the research progress of equol and its derivatives in recent years, with a focus on the expansion of the synthetic mechanism and pathway of equol and its derivatives, and the exploration of the biological activities and functional development of equol and its derivatives. These advances will lay the foundation for the development of equol based nutrition and targeted therapy, thus providing new ideas and methods for the treatment of related diseases.

27 June 2024 in Foods
Verified
Journal Article
Open access
PDF file
PLPing Li
Ping Li
WSWen-Jun Song
Wen-Jun Song
YWYumeng Wang
Yumeng Wang
XLXin Li
Xin Li
SWShankai Wu
Shankai Wu
CZCuiying Zhang
Cuiying Zhang
During malolactic fermentation (MLF) of vinification, the harsh L–malic acid undergoes transformation into the milder L–lactic acid, and via decarboxylation reactions it is catalyzed by malolactic enzymes in LAB. The use of bacterial malolactic starter cultures, which usually present challenges in the industry as the suboptimal conditions after alcoholic fermentation (AF), including nutrient limitations, low temperatures, acidic pH levels, elevated alcohol, and sulfur dioxide concentrations after AF, lead to “stuck” or “sluggish” MLF and spoilage of wines. Saccharomyces uvarum has interesting oenological properties and provides a stronger aromatic intensity than Saccharomyces cerevisiae in AF. In the study, the biological pathways of deacidification were constructed in S. uvarum, which made the S. uvarum carry out the AF and MLF simultaneously, as different genes encoding malolactic enzyme (mleS or mleA), malic enzyme (MAE2), and malate permease (melP or MAE1) from Schizosaccharomyces pombe, Lactococcus lactis, Oenococcus oeni, and Lactobacillus plantarum were heterologously expressed. For further inquiry, the effect of L–malic acid metabolism on the flavor balance in wine, the related flavor substances, higher alcohols, and esters production, were detected. Of all the recombinants, the strains WYm1SN with coexpression of malate permease gene MAE1 from S. pombe and malolactic enzyme gene mleS from L. lactis and WYm1m2 with coexpression of gene MAE1 and malate permease gene MAE2 from S. pombe could reduce the L–malic acid contents to about 1 g/L, and in which the mutant WYm1SN exhibited the best effect on the flavor quality improvement.

18 February 2026 in Molecules
Verified
Journal Article
Open access
PDF file
BLBingjuan Li
Bingjuan Li
JZJiaojiao Zhuo
Jiaojiao Zhuo
MTMeng-Ran Tian
Meng-Ran Tian
DMDan Meng
Dan Meng
HLhongyan li
hongyan li
As an isoflavone metabolite with diverse physiological activities, the development of efficient and sustainable manufacturing technologies for (S)-equol holds significant importance. This study focuses on the semi-rational design of daidzein reductase (DZNR), the first key enzyme in the (S)-equol biotransformation pathway. Through multiple sequence alignment and three-dimensional structural analysis, two critical residues, Gly30 and Ala105, were identified in DZNR. A library of single and combinatorial mutants was constructed and screened, yielding the double variant DZNR30S+105S with substantially enhanced catalytic performance. In a whole-cell biocatalytic system, the recombinant E. coli (Escherichia coli) strain harboring this combinatorial mutant achieved a yield of 238.3 mg/L (S)-equol at a substrate concentration of 1 mM daidzein, demonstrating markedly improved catalytic efficiency. Upon increasing the daidzein concentration to 2 mM, the reaction reached equilibrium within 5 h, producing 384.6 mg/L (S)-equol, which highlights the mutant’s excellent potential for high-substrate-concentration applications. This study not only provides novel mechanistic insights into DZNR catalysis but also successfully establishes a DZNR variant with enhanced activity, offering an efficient biocatalytic component for the industrial-scale biomanufacturing of (S)-equol and thereby advancing the development of green biosynthesis technologies for this valuable compound.